Zai Lab Reports Topline Data From Phase 3 Bridging Trial Evaluating KarXT For Schizophrenia In China; KarXT Demonstrated A Statistically Significant 9.2-Point Reduction In PANSS Total Score From Baseline At Week 5 Compared To Placebo, Trial Met All Secondary Endpoints
Portfolio Pulse from Benzinga Newsdesk
Zai Lab has reported positive topline data from its Phase 3 trial of KarXT for schizophrenia in China. The trial showed a significant reduction in PANSS total score and met all secondary endpoints.
October 29, 2024 | 11:39 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Zai Lab's Phase 3 trial of KarXT for schizophrenia in China demonstrated significant efficacy, with a 9.2-point reduction in PANSS score and all secondary endpoints met.
The successful Phase 3 trial results for KarXT in China are likely to boost investor confidence in Zai Lab, as the drug demonstrated significant efficacy and met all secondary endpoints. This could lead to positive market sentiment and a potential increase in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100